Schizophrenia Research
Volume 113, Issue 2 , Pages 129-137 , September 2009

Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study)

  • Immaculada Baeza

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychology, Institut Clinic of Neurosciences, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • Corresponding Author InformationCorresponding author. Department of Child and Adolescent Psychiatry and Psychology, Institut Clínic of Neurosciences, Hospital Clínic Universitari, C/Villarroel, 170, Barcelona 08036, Spain. Tel./fax: +34 93 2279974.
    • ,
  • Montserrat Graell

      Affiliations

    • Section of Child and Adolescent Psychiatry and Psychology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
    • ,
  • Dolores Moreno

      Affiliations

    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • Adolescent Unit, Department of Psychiatry. Hospital General Universitario Gregorio Marañón, Madrid, Spain
    • ,
  • Josefina Castro-Fornieles

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychology, Institut Clinic of Neurosciences, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • ,
  • Mara Parellada

      Affiliations

    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • Adolescent Unit, Department of Psychiatry. Hospital General Universitario Gregorio Marañón, Madrid, Spain
    • ,
  • Ana González-Pinto

      Affiliations

    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • Stanley Institute International Mood-Disorders Research Center, 03-RC-003, Hospital Santiago Apóstol, Vitoria, Spain
    • ,
  • Beatriz Payá

      Affiliations

    • Child and Adolescent Mental Health Unit. Department of Psychiatry and Psychology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
    • ,
  • César Soutullo

      Affiliations

    • Child and Adolescent Psychiatry Unit, Department of Psychiatry and Medical Psychology, University Clinic, College of Medicine, University of Navarra, Pamplona, Spain
    • ,
  • Elena de la Serna

      Affiliations

    • Department of Child and Adolescent Psychiatry and Psychology, Institut Clinic of Neurosciences, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • ,
  • Celso Arango

      Affiliations

    • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain
    • Adolescent Unit, Department of Psychiatry. Hospital General Universitario Gregorio Marañón, Madrid, Spain

Received 6 May 2008 ,Revised 4 April 2009 ,Accepted 7 April 2009.

References 

  1. Addington J, Addington D. Effect of substance misuse in early psychosis. British Journal of Psychiatry. 1998;172(Suppl 33):134–136
  2. Archie S, Rush BR, Akhtar-Danesh N, Norman R, Malla A, Roy P, et al. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophrenia Bulletin. 2007;33:1354–1363
  3. Barnes TRE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry. 2006;188:237–242
  4. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Research. 1982;26:351–366
  5. Caspari D. Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychatry and Clinical Neuroscience. 1999;249:45–49
  6. Castro-Fornieles J, Parellada M, González-Pinto A, Moreno D, Graell M, Baeza I, et al. The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. Schizophrenia research. 2007;91:226–237
  7. Cohen M, Solowij N, Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Australian and New Zealand Journal of Psychiatry. 2008;42:357–368
  8. De la Peña F, Ulloa R, Higuera F, Ortiz S, Arechavaleta B, Foullux C, et al. Interrater reliability of the Spanish version of the K-SADS-PL. In: American Academy of Child and Adolescent Psychiatry, Annual Meeting, San Francisco, CA, 2002. Scientific Proceedings, NR Poster. vol. A35:2002;p. 96
  9. Deas-Nesmith D, Campbell S, Brady KT. Substance use disorders in an adolescent inpatient psychiatric population. Journal of the National Medical Association. 1998;90:233–238
  10. Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, et al. Randomized control trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica. 2004;114:109–117
  11. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry. 1976;33:766–771
  12. González-Pinto A, Vega P, Ibáñez B, Mosquera F, Barbeito S, Gutierrez M, et al. Impact of cannabis and other drugs on age at onset of psychosis. Journal of Clinical Psychiatry. 2008;69:1210–1216
  13. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. European Psychiatry. 2005;20:349–353
  14. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, et al. First-episode schizophrenia related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research. 2004;66:125–135
  15. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Australian and New Zealand Journal of Psychiatry. 2000;34:468–475
  16. Hamilton M. Development of a rating scale for a primary depressive illness. British Journal of Sociology and Clinical Psychology. 1967;6:278–296
  17. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. Journal of Affective Disorders. 2006;95:103–110
  18. Hollingshead AB, Redlich F. In: Social Class and Mental Illness. NY: John Wiley & Sons Inc; 1958;p. 387–397
  19. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36:980–988
  20. Kay SR, Fiszbein A, Opler LA. The risk for psychiatric disorders in relatives of schizophrenic and control probands: a comparison of three independent studies. Psychological Medicine. 1987;27:411–419
  21. Krystal, J.H., D'Souza, D.C., Madonick, S., Petrakis, I.L., 1999. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 35 Suppl, S35–S49.
  22. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica. 2005;112:141–148
  23. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addiction Biology. 2008;13:264–275
  24. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Archives of General Psychiatry. 1994;51:273–279
  25. Mauri MC, Volonteri LS, De Gaspari IF, Colasanti A, Brambilla MA, Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clinical Practice and Epidemiology in Mental Health. 2006;2:4
  26. Moore THM, Zammit S, Lingford-Hugues A, Barnes TRE, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328
  27. Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Reviews. 2008;8:1037–1048
  28. Observatorio español sobre drogas. Informe de la encuesta estatal sobre uso de drogas de estudiantes de secundaria (ESTUDES) 2006–2007, 2007. Delegacion del Gobierno para el Plan Nacional sobre Drogas. Secretaria General de Sanidad. Ministerio de Sanidad y Consumo.
  29. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Research. 2005;133:35–43
  30. Peralta V, Cuesta M. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Españolas de Neurología y Psiquiatría. 1994;22:171–177
  31. Ravinowitz J, Bromet EJ, Lavelle J, Carlson J, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine. 1998;28:1411–1419
  32. San L, Arranz B, Martínez-Raga J. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. European Addiction Research. 2007;13:230–243
  33. Sevy S, Robinson DG, Solloway S, Alvir JM, Woerner MG, Bilder R, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica. 2001;104:367–374
  34. Sugrañes G, Flamarique I, Parellada E, Baeza I, Goti J, Fernández-Egea E, et al. Cannabis use and age of diagnosis of schizophrenia. European Psychiatry. 2009;24:mar (electronic publication)
  35. Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ. Comorbid substance-use in schizophrenia. Relation to positive and negative symptoms. Schizophrenia Research. 2006;86:251–255
  36. Ulloa RE, Ortiz S, Higuera F, Nogales I, Fresan A, Apiquian R, et al. Interrater reliability of the Spanish version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime version (K-SADS-PL). Actas Españolas de Psiquiatría. 2006;34:36–40
  37. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology. 2004;39:69–72
  38. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry. 2004;161:501–506
  39. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry. 2006;189:229–234
  40. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry. 1978;133:429–435
  41. Zammit S, Moore THM, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry. 2008;193:357–363

PII: S0920-9964(09)00168-6

doi: 10.1016/j.schres.2009.04.005

Schizophrenia Research
Volume 113, Issue 2 , Pages 129-137 , September 2009

Article Tools

* Image Usage & Resolution